Discovery of molecular glues for modulating MHC presentation of cancer neoantigens
In the authors' words
Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.
In plain words AI summary
The researchers found chemical compounds called peptide MHC glues that help these antigens form complexes with MHC class I. Crystal structures revealed that the compounds stabilize binding by touching both the MHC protein and the antigen peptides at once. This work offers a new chemical method to alter MHC antigen presentation and reach rare cancer antigens for treatment.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source. 1 sentence was removed for not being supported by the abstract.
Appeared: Sunday, November 15. bioRxiv. Preprint, not yet peer-reviewed.